{"entity":{"id":"ceacam5","kind":"target","name":"CEACAM5","aka":[],"tldr":"The classic 'CEA' tumour marker measured in blood, also present on the cell surface where ADCs can reach it.","summary":"CEACAM5 is carcinoembryonic antigen, a GPI-anchored adhesion molecule that is shed into circulation as the serum CEA marker and also sits on the cell surface where ADCs and T-cell engagers can reach it. It is overexpressed in colorectal (80-90% moderate-to-high by IHC), gastric (50-60%), lung adenocarcinoma, and pancreatic cancers; only 20-25% of non-squamous NSCLC met the high-expression threshold used in CARMEN. Tusamitamab ravtansine failed in phase 3 NSCLC (CARMEN-LC03), a setback that raised questions about payload choice and patient selection rather than the target itself. CEACAM5 remains pursued with T-cell engagers and next-generation ADCs. The simple version is the classic CEA blood marker, now also being used as a surface target for drug delivery.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Carcinoembryonic_antigen","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Carcinoembryonic_antigen"}],"tags":["adc-target","biomarker"],"related":["ceacam5-expression"],"cancers":["colorectal","nsclc","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["sgm-101","precemtabart-tocentecan","ose2101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07589517","nct07462650"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"CEACAM5","role":[],"sources":[],"specificity":"tumour-associated","distribution":"few-types","specificityNote":"Tumour-associated overexpression: 3 cell-killing or cell-finding medicines (SGM-101, Precemtabart tocentecan, Tusamitamab ravtansine) aim at the antigen, which HPA finds stained high in 3 normal tissues; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA CEACAM5: RNA tissue enriched (intestine 920 nTPM); high antibody staining in 3 normal tissues; highest cancer staining colorectal cancer (6 of 10 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Lung cancer (all types), Gastric & gastro-oesophageal junction cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas CEACAM5 tissue","url":"https://www.proteinatlas.org/ENSG00000105388-CEACAM5/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas CEACAM5 pathology","url":"https://www.proteinatlas.org/ENSG00000105388-CEACAM5/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000105388 associations","url":"https://platform.opentargets.org/target/ENSG00000105388/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:1817","ensembl":"ENSG00000105388","uniprot":"P06731","entrez":"1048","firstDescribed":1987,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Beauchemin et al, Mol. Cell. Biol, 1987, \"Isolation and characterization of full-length functional cDNA clones for human carcinoembryonic antigen\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/3670312/","biology":"GPI-anchored adhesion molecule; shed into circulation as the serum CEA marker.","whereFound":["Colorectal","Gastric","Lung adenocarcinoma","Pancreatic"],"targetClass":"surface-antigen","prevalence":[{"cancerId":"colorectal","pct":"80-90","measure":"IHC, moderate-high","source":"https://en.wikipedia.org/wiki/Carcinoembryonic_antigen"},{"cancerId":"nsclc","pct":"20-25","measure":"High expression (>=50% cells 2+/3+)","source":"https://en.wikipedia.org/wiki/Carcinoembryonic_antigen","note":"Non-squamous, CARMEN threshold"},{"cancerId":"gastric","pct":"50-60","measure":"IHC, any expression","source":"https://en.wikipedia.org/wiki/Carcinoembryonic_antigen"}]},"route":"/targets/ceacam5/","neighbours":{"biomarker":[{"id":"ceacam5-expression","kind":"biomarker","name":"CEACAM5 expression","route":"/biomarkers/ceacam5-expression/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"ose2101","kind":"drug","name":"OSE2101","route":"/drugs/ose2101/"},{"id":"precemtabart-tocentecan","kind":"drug","name":"Precemtabart tocentecan","route":"/drugs/precemtabart-tocentecan/"},{"id":"sgm-101","kind":"drug","name":"SGM-101","route":"/drugs/sgm-101/"},{"id":"tusamitamab-ravtansine","kind":"drug","name":"Tusamitamab ravtansine","route":"/drugs/tusamitamab-ravtansine/"}],"trial":[{"id":"nct07462650","kind":"trial","name":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07462650/"},{"id":"nct07589517","kind":"trial","name":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07589517/"}],"idea":[{"id":"idea-bio1-antigen-mapping-at-progression","kind":"idea","name":"Re-map the tumour's surface proteins before choosing the next antibody drug","route":"/ideas/idea-bio1-antigen-mapping-at-progression/"}],"institution":[{"id":"mcgill-goodman","kind":"institution","name":"Rosalind and Morris Goodman Cancer Institute, McGill University","route":"/institutions/mcgill-goodman/"}],"pathway":[{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/"}],"technology":[{"id":"cea-surveillance-colorectal","kind":"technology","name":"CEA surveillance after colorectal cancer surgery","route":"/technologies/cea-surveillance-colorectal/"},{"id":"serum-tumour-markers","kind":"technology","name":"Serum tumour markers: proper use and misuse","route":"/technologies/serum-tumour-markers/"},{"id":"thyroid-cancer-markers","kind":"technology","name":"Thyroglobulin, calcitonin and CEA in thyroid cancer follow-up","route":"/technologies/thyroid-cancer-markers/"}]}}